Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPain ManagementAetna PHN Coverage & Prior Auth Policy Update | Op…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0725

    Post-Herpetic Neuralgia (PHN)

    Customize your policy alerts

    Sign up for Aetna Policy 0725 alerts

    Get alerted when Policy 0725 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Aetna's coverage stance for therapies used to prevent and treat post-herpetic neuralgia and lists interventions considered experimental/investigational. Applies to Aetna medical benefits and providers seeking coverage for PHN-related treatments.

    Policy Summary
    PayerAetna
    PolicyPost-Herpetic Neuralgia (PHN)
    Policy CodePolicy 0725
    Change TypeNo material change
    Effective DateJun 20, 2006
    Last ReviewOct 20, 2025
    Next Review DateAug 13, 2026
    Key ActionDocument a prior trial and inadequate response to guideline-recommended first-line pharmacologic therapy (e.g., gabapentin or pregabalin) before escalating to invasive procedures.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    36+experimental/unproven listed
    CPT/HCPCS/ICDcode listings
    3 monthsPHN timing
    402Qutenza trial patients
    >=5%PHN prevalence (elderly)

    Coverage Determinations and Evidence Summary

    Covered therapies vs Experimental/Investigational

    Aetna considers the following therapies medically necessary for PHN and lists numerous other modalities as experimental, investigational, or unproven:

    Medically necessary therapies: Aetna considers the use of oral antivirals, gabapentin, intrathecal, interlaminar or transforaminal epidural corticosteroids, lidocaine patch (5%), oral opioids, pregabalin, and tricyclic antidepressants medically necessary for post‑herpetic neuralgia (PHN).

    From policy scope

    Experimental/Investigational/Unproven therapies: The policy lists multiple diagnostic and therapeutic modalities considered experimental, investigational, or unproven for PHN (examples include: acupoint herbal patching; acupuncture; angiotensin II type 2 receptor antagonists (EMA401); blood‑letting and cupping; botulinum toxin; combined pulsed radiofrequency + transforaminal epidural steroid injection; combined nerve block + PRF; trigeminal ganglion + retrobulbar block; cryocautery; dorsal root entry zone lesions/DRG destruction; epidural morphine; extracorporeal shockwave therapy; fulranumab; ganglioside GM1; intercostal nerve block; intralesional corticosteroid; IV antiviral, ketamine, lidocaine, vitamin C, zinc sulfate; iontophoresis of vincristine; laser irradiation; narrow‑band UVB; ozone injection into the intervertebral foramen; peripheral nerve stimulation; pulsed radiofrequency of the dorsal root ganglion; serum miR‑34c‑5p for diagnosis; stellate ganglion blockade; sympathectomy; thermotherapy (fire needle, moxibustion); topical ketamine/piroxicam; transcranial magnetic stimulation; transcutaneous electrical nerve stimulation (TENS); transdermal oxycodone patch; trigeminal nerve block and others).
    Policy Summary
    PayerAetna
    PolicyPost-Herpetic Neuralgia (PHN)
    Policy CodePolicy 0725
    Change TypeNo material change
    Effective DateJun 20, 2006
    Last ReviewOct 20, 2025
    Next Review DateAug 13, 2026
    Key ActionDocument a prior trial and inadequate response to guideline-recommended first-line pharmacologic therapy (e.g., gabapentin or pregabalin) before escalating to invasive procedures.
    SourceLink
    On This Page
    Coverage Determinations and Evidence SummaryProcedural and Diagnosis CodesPrior Authorization, Documentation, and Provider RequirementsConservative Therapy Preconditions for InterventionsApplication and Repeat IntervalsImaging Guidance and Procedural Modality NotesInterventions Considered Experimental / Not Medically NecessaryDefinitions and Key Term ReferencesPolicy Dates and Revision Notes

    Complete enumerated list appears in policy chunks 4–5

    Evidence summaries and recommended/unsupported therapies

    Key clinical evidence and guideline recommendations summarized:

    Guideline‑endorsed therapies: Tricyclic antidepressants, gabapentin, pregabalin, opioids and 5% lidocaine patch are considered effective and should be used in the treatment of PHN (per AAN and guideline summaries).

    Source: AAN/clinical guidance (chunks 16,20)

    High‑concentration capsaicin patch (Qutenza/NGX‑4010): Randomized trials (Backonja et al., 2008; multinational trials) demonstrated a single 60‑minute application of an 8% capsaicin patch produced statistically significant pain reduction versus low‑concentration control; product labeling requires application by a health‑care professional with topical anesthetic and monitoring, and permits repeat applications not more frequently than every 3 months.repeat ≥3 months

    Sources: Backonja RCT (chunk 28), FDA approval and product labeling (chunk 33)

    Corticosteroids to prevent PHN: Meta‑analyses and randomized trials (Cochrane review) provide moderate‑quality evidence that systemic corticosteroids given acutely do not prevent PHN at 6 months; corticosteroids may relieve acute zoster pain but are not supported for PHN prevention.

    Sources: Cochrane review/updates (chunks 37–38)

    Interventional and alternative therapies: Evidence for many interventions (SCS, intrathecal methylprednisolone, peripheral nerve stimulation, sympathetic or stellate blocks, nbUVB, topical (S)‑ketamine, IV lidocaine, TENS, rTMS, PRF of DRG, IV ozone, others) is limited, preliminary, or mixed; larger well‑designed randomized trials are generally needed before broad endorsement.

    Sources: multiple background trials and reviews (chunks 36,37,43,47,67,68,94)

    Evidence summaries by intervention

    Summarized evidence findings by intervention (evidence quality and key results):

    nbUVB: Pilot nbUVB (17 patients) showed some patients achieved >50% improvement at end of therapy and at 3‑month follow‑up, but sample size was small and findings require validation in larger trials.

    chunk 36

    Topical (S)‑ketamine: Small crossover trial (12 patients) found no significant difference versus placebo; only mild cutaneous reactions observed.

    chunk 36

    Corticosteroids for prevention of PHN: Cochrane review of 5 RCTs (787 participants) provided moderate‑quality evidence that oral corticosteroids given acutely do not prevent PHN at 6 months; adverse events similar to placebo.

    chunks 37–38

    Levetiracetam: Systematic review pooled small studies across neuropathic conditions and found no convincing analgesic effect; evidence rated low/very low quality.

    chunk 39

    Oxycodone / transdermal oxycodone patch: Cochrane reviews and RCTs provide very low‑quality evidence for benefit in PHN; adverse events are common and trials show limited or inconsistent analgesia for the patch formulation.

    chunks 41,52,53

    TENS with biofeedback device: Pilot randomized study in refractory PHN showed significant pain score decrease versus sham; further investigation needed given small pilot design.

    chunk 43

    AT2R antagonist (EMA401/EMA401 trials): Phase IIb trials were terminated early for preclinical hepatotoxicity concerns; numerical trends favored active dose but trials were underpowered due to premature termination, limiting conclusions.

    chunk 44

    CT‑guided PRF to thoracic DRG: A retrospective series (n=109) reported greater efficacy at higher PRF voltage (65 V) with acceptable safety; authors call for larger multicenter RCTs.

    chunk 47

    Low‑level laser therapy (LLLT) for PHN prevention: Retrospective study suggested applying LLLT within first 5 days of rash reduced PHN incidence at 1, 3, and 6 months after adjustment, but design limits causal inference and RCTs are needed.

    chunk 51

    Combined NBT + PRF (Li et al.): Small randomized single‑center trial (n=60) reported reduced VAS and favorable biomarker changes for combined nerve block + PRF versus controls; authors noted small sample and single‑center design.

    chunk 54

    Evidence summaries for specific interventions

    Evidence synthesis and applicability considerations for specific interventional or adjunct therapies:

    Combined Nerve Block + PRF: Small RCT (Li et al., 2018; n=60) reported that combined nerve block therapy plus pulsed radiofrequency reduced pain (VAS) and altered inflammatory/neuropeptide biomarkers versus control; study authors emphasize single‑center design and need for larger trials.study‑level evidence; small RCT

    chunks 54–55

    Intravenous zinc sulfate (add‑on): Case reports (2 patients) of IV zinc sulfate added to pregabalin in zinc‑deficient PHN patients reported clinical response; preliminary case‑report evidence requiring validation in controlled studies.case‑report evidence

    chunk 56

    DRG PRF combined with gabapentin: Randomized and nonrandomized studies report improved VAS and biomarker changes when PRF to the dorsal root ganglion is combined with gabapentin versus gabapentin alone; methodological limitations and short follow‑up constrain conclusions.small RCTs / retrospective cohorts

    chunks 57–61

    Transforaminal epidural steroid injection (TF ESI): Case reports and cohort data indicate TF or interlaminar epidural steroid injections may reduce acute shingles pain in selected refractory patients, but RCT data do not consistently favor one approach; early poor response (<50% improvement at 1 week) after TF ESI predicted progression to PHN in at least one cohort.mixed low‑level evidence

    chunks 62–64

    rTMS: Small RCTs and a recent meta‑analysis (Dai et al., 2024) of 5 RCTs (257 patients) suggest rTMS may reduce VAS and improve patient‑reported outcomes versus sham; heterogeneity across stimulation parameters and small study sizes limit definitive protocol recommendations.small RCTs / meta‑analysis

    chunks 68–70

    Trigeminal ganglion / peripheral nerve blocks: Case reports/series describe successful trigeminal ganglion plus retrobulbar blocks and peripheral nerve blocks (including BoNT‑A under ultrasound guidance) for refractory ophthalmic‑division PHN or focal PHN after failure of conservative therapies; single‑case and small series report benefit but also rare serious ocular complications (neurotrophic keratopathy) reported after Gasserian ganglion block.case reports/series

    chunks 46,71–73

    The policy lists specific CPT and HCPCS procedure and supply codes referenced in the coverage criteria. Examples include covered injectable and epidural procedure codes when selection criteria are met (e.g., interlaminar and transforaminal epidural injection codes 62320-62327 and 64479/64483) as well as multiple CPT codes designated as not covered for the indications in this Clinical Policy Bulletin (examples: 0101T, 0228T-0231T, 62281-62282, 63650, 63655, 64400, 64420-64421, 64510, 64555, 64575, 64600-64640, 64680-64681, 64802-64818, 67500-67505, 90867-90869, 96910, 97033, 97810-97814).

    HCPCS/J-codes and other injectable codes are also listed; several corticosteroid HCPCS codes (e.g., J1020-J2930, J3300-J3303) are shown as covered if selection criteria are met, while other HCPCS codes and supplies (e.g., A4595; E0720, E0730, E0731 for TENS devices/supplies; J0133 acyclovir injection; J0585/J0587 botulinum toxin) are enumerated among not-covered or mixed-status lists. The policy also identifies the ICD-10 diagnosis range for zoster with nervous system involvement (B02.21-B02.29) as the covered diagnostic codes when selection criteria are met.

    The policy summarizes multiple therapies discussed in the evidence review and inventory. These include conservative pharmacologic options (tricyclic antidepressants, gabapentin, pregabalin, oral antivirals, opioids and lidocaine patch) and numerous adjunct or alternative therapies: acupuncture, acupoint herbal patching, blood‑letting puncture and cupping, extracorporeal shockwave therapy, laser irradiation, narrow‑band UVB, moxibustion/thermotherapy, topical agents (e.g., topical piroxicam, topical ketamine), high‑concentration capsaicin patch (Qutenza/NGX‑4010), intravenous agents (vitamin C, zinc, ketamine, lidocaine), ozone injection into the intervertebral foramen, pulsed radiofrequency (DRG PRF), transforaminal or interlaminar epidural steroid injections, trigeminal/retrobulbar nerve blocks, peripheral nerve stimulation, spinal cord stimulation, repetitive transcranial magnetic stimulation (rTMS/TMS), and transcutaneous electrical nerve stimulation (TENS).

    The policy notes that intravenous (IV) lidocaine and neuromodulatory devices or procedures such as TENS and acupuncture are discussed in the literature as having insufficient or unproven evidence for PHN. UpToDate and Cochrane reviews emphasize that IV lidocaine may show benefit in refractory cases but small controlled trials have not convincingly demonstrated superiority to placebo, and TENS/acupuncture effectiveness has not been proven. The document separately identifies topical lidocaine as a therapeutic option supported by randomized trial data and meta-analysis.

    An UpToDate review cited in the policy (Ortega, 2020) specifically states that the effectiveness of therapies such as transcutaneous electrical nerve stimulation (TENS), transcranial magnetic stimulation (TMS/rTMS), and acupuncture has not been proven for PHN. The same UpToDate source does not list trigeminal nerve block among established therapeutic options for PHN, reflecting limited endorsement of these modalities in that clinical reference.

    The policy highlights safety signals reported in case literature: a published case report described ocular complications after a trigeminal (Gasserian) ganglion block, including declining visual acuity, severe corneal epithelial defects, neurotrophic keratopathy and prolonged corneal sensory changes, illustrating potential risks when performing blocks near ocular structures.

    Throughout the evidence summaries the authors repeatedly note the limitations of the existing literature: many positive findings derive from small, single‑center trials, retrospective cohorts, or pilot studies and heterogeneity of methods and endpoints is common. The document concludes that larger, well‑designed randomized controlled trials are needed to validate preliminary or promising results before broader adoption, and no new explicit coverage exclusions beyond those enumerated are added in these sections.

    This Clinical Policy Bulletin is intended to assist in administering plan benefits and is not a substitute for individualized medical judgment. It does not constitute an offer of coverage or medical advice, contains only a partial description of plan benefits, and may be updated; treating providers retain responsibility for medical advice and treatment of members.

    The policy states that any modality explicitly listed as experimental, investigational, or unproven for PHN is considered not established in effect for this indication. Therapies placed in that list are therefore treated as not medically necessary for PHN unless future evidence changes their status.

    Systematic reviews and randomized trials summarized in the policy found that administration of corticosteroids during acute herpes zoster does not prevent post‑herpetic neuralgia. Multiple RCTs pooled in Cochrane reviews showed no significant reduction in the incidence of PHN at 6 months with corticosteroid use during acute HZ.

    Updated analyses similarly reported moderate‑quality evidence that corticosteroids given acutely are ineffective in preventing PHN at 6 months, though they may relieve acute zoster pain; the policy therefore does not support routine corticosteroid use for PHN prevention.

    A Cochrane meta‑analysis updated in 2013 provided moderate‑quality evidence that oral corticosteroids given during acute herpes zoster did not prevent PHN at 6 months (meta‑analysis of trials resulted in no significant difference versus placebo), supporting the policy position that corticosteroids are not effective for PHN prevention.

    Many sections of the review characterize evidence as preliminary or limited quality: pilot studies (e.g., nbUVB, small crossover trials), small randomized single‑center trials (e.g., combined nerve block + PRF), and retrospective case series (e.g., CT‑guided DRG PRF or combined PRF/TFAESI). Authors consistently note methodological limitations, small sample sizes, and the need for confirmatory multicenter randomized trials.

    Procedural and Diagnosis Codes

    Covered CPT Codes (when selection criteria are met)CPTCovered
    62320-62321Injection(s), of diagnostic or therapeutic substance(s) (eg, anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, including needle or catheter placement, interlaminar epidural or subarachnoid, cervical or thoracic.
    62322-62323Injection(s), of diagnostic or therapeutic substance(s) (eg, anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, including needle or catheter placement, interlaminar epidural or subarachnoid, lumbar or sacral (caudal).
    62324-62325Injection(s), including indwelling catheter placement, continuous infusion or intermittent bolus, of diagnostic or therapeutic substance(s) (eg, anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, interlaminar epidural or subarachnoid, cervical or thoracic.
    62326-62327Injection(s), including indwelling catheter placement, continuous infusion or intermittent bolus, of diagnostic or therapeutic substance(s) (eg, anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, interlaminar epidural or subarachnoid, lumbar or sacral (caudal).
    64479Injection(s), anesthetic agent and/or steroid, transforaminal epidural, with imaging guidance (fluoroscopy or CT); cervical or thoracic, single level.
    64480cervical or thoracic, each additional level (List separately in addition to code for primary procedure).
    64483Injection(s), anesthetic agent and/or steroid, transforaminal epidural, with imaging guidance (fluoroscopy or CT); lumbar or sacral, single level.
    64484lumbar or sacral, each additional level (List separately in addition to code for primary procedure).
    CPT codes not covered for indications listed in the CPB (not all-inclusive)CPTNot Covered
    0101TExtracorporeal shock wave involving musculoskeletal system, not otherwise specified, high energy.
    0228T-0229TInjection(s), anesthetic agent and/or steroid, transforaminal epidural, with ultrasound guidance; cervical or thoracic; single level and each additional level.
    0230T-0231TInjection(s), anesthetic agent and/or steroid, transforaminal epidural, with ultrasound guidance; lumbar or sacral; single level and each additional level.
    62281-62282Injection/infusion of neurolytic substance (eg, alcohol, phenol, iced saline solutions), with or without other therapeutic substance; epidural.
    63650Percutaneous implantation of neurostimulator electrode array, epidural.
    63655Laminectomy for implantation of neurostimulator electrodes, plate/paddle, epidural.
    64400Injection, anesthetic agent; trigeminal nerve, any division or branch.
    64420-64421Injection, anesthetic agent; intercostal nerve, single; and intercostal nerves, multiple, regional block.
    64510Injection, anesthetic agent; stellate ganglion (cervical sympathetic).
    64555Percutaneous implantation of neurostimulator electrodes; peripheral nerve (excludes sacral nerve).
    1–10 of 20
    1/2
    HCPCS codes (covered and not-covered lists mixed as presented)HCPCS
    J1020-J1040Injection, methylprednisolone acetate (20 mg, 40 mg, 80 mg) — injectable corticosteroids listed as covered if selection criteria are met.
    J1094Injection, dexamethasone acetate, 1 mg.
    J1100Injection, dexamethasone sodium phosphate, 1 mg.
    J1320Injection, amitriptyline HCL, up to 20 mg.
    J1700-J1720Injection, hydrocortisone acetate or hydrocortisone sodium formulations (various strengths).
    J2650Injection, prednisolone acetate, up to 1 ml.
    J2920-J2930Injection, methylprednisolone sodium succinate (up to 40 mg and up to 125 mg).
    J3300-J3303Triamcinolone injectable codes (various formulations/strengths).
    99601-99602Home infusion/specialty drug administration, per visit.
    J0133Injection, acyclovir, 5 mg (listed as not covered).
    1–10 of 14
    1/2
    ICD-10 diagnosis codes covered if selection criteria are metICD-10Covered
    B02.21-B02.29Zoster [herpes zoster] with other nervous system involvement.
    PHN timing — definition
    Definition (timing)Post-herpetic neuralgia (PHN) — significant pain or dysaesthesia present 3 months or more following acute herpes zoster.
    Clinical contextPHN is the most common complication of herpes zoster and is diagnosed clinically by typical unilateral dermatomal pain and rash following acute HZ.
    Population prevalence noteMore than 5% of elderly patients have PHN at 1 year after acute HZ.
    Relation to immune statusIncidence of HZ and subsequent PHN increases with reduced cell-mediated immunity (age, malignancy, HIV, immunosuppressive drugs).
    Acute management linkagePatients with acute HZ are treated with antivirals (e.g., acyclovir, valacyclovir) but PHN is defined by persistent pain ≥3 months despite acute-phase treatment.
    Coding guidance inclusionUse the PHN timing definition (pain/dysaesthesia ≥3 months after acute HZ) when applying PHN-related ICD-10 and procedure coding in this policy (e.g., B02.21–B02.29 where selection criteria are met).

    Prior Authorization, Documentation, and Provider Requirements

    Prior Authorization

    Procedures/injectables require selection criteria — possible prior authorization

    Submit claims using the listed CPT/HCPCS/ICD-10 codes only when the policy's selection criteria are met; certain interlaminar (62320–62327) and transforaminal epidural injection codes (64479, 64483) and injectable corticosteroid HCPCS (J1020–J2930 range) are covered when criteria are satisfied and may require prior authorization per plan procedures.

    • Use CPT codes 62320–62327 for interlaminar epidural injections when selection criteria are met.
    • Use CPT codes 64479 and 64483 for transforaminal epidural injections with imaging guidance (fluoroscopy or CT) as described.
    • Bill appropriate HCPCS corticosteroid codes (J1020–J2930) only when policy selection criteria are documented.
    Prior Authorization

    Prior authorization note — clinician-applied capsaicin patch (Qutenza)

    Qutenza (8% capsaicin patch) is a clinician-applied, procedure‑like therapy; if requested, prior authorization justification should document indication (PHN), adherence to application parameters, and prior therapies tried.

    • Qutenza must be applied by a health care professional and is administered to the most painful areas (up to 4 patches; 60 minutes application).
    • Document prior treatments and refractory status if payer requires prior authorization for topical high‑concentration capsaicin.
    Note

    No explicit prior authorization specified in these excerpts

    This excerpt does not specify concrete prior authorization codes or explicit plan PA rules; consult the Clinical Policy Bulletin Notes and member plan provisions for any plan‑specific PA requirements.

    • No specific PA codes or mandates are present in these document chunks.
    • Plan provisions or Clinical Policy Bulletin Notes may define PA processes for your patient.
    Prior Authorization

    Prior authorization justification — thoracic TF ESI: document prior therapy failures

    For thoracic transforaminal epidural steroid injections used for refractory PHN, expect to provide documentation of failure of prior oral/topical medications and prior nerve/intercostal blocks plus baseline and follow-up pain scores to justify use.

    • Record prior conservative treatments attempted (oral and topical agents) and any prior intercostal or peripheral nerve blocks.
    • Include baseline and post-procedure pain assessments (e.g., VAS/NRS at 1 week and subsequent follow-ups).
    Prior Authorization

    Prior authorization justification — capsaicin 8% patch (Qutenza)

    If payer prior authorization is required for high‑concentration (8%) capsaicin patch, justify with evidence of refractory neuropathic pain/PHN and documentation of prior therapy failure; observational series and cohorts form the primary evidence base referenced.

    • Cite PHN diagnosis, baseline pain intensity (VAS/NRS), prior systemic and topical therapies, and response history.
    • Note that evidence cited includes randomized trials for Qutenza and observational cohorts for other neuropathic pain populations.
    Note

    No explicit prior authorization codes specified for CT/fluoroscopy-guided interventional studies

    The document includes procedural descriptions performed under CT or fluoroscopic guidance but does not list concrete prior authorization codes for those interventional studies; verify plan PA requirements locally.

    • Studies describe CT- or fluoroscopy-guided procedures (e.g., IVFO, DRG PRF + TFAESI) without specifying PA codes.
    • Confirm with the member's plan whether PA is required and which codes apply.
    Note

    Prior authorization referenced — consult Clinical Policy Bulletin Notes and plan provisions

    The policy references Clinical Policy Bulletin Notes and plan provisions for administering benefits; providers should consult those resources for plan‑specific prior authorization rules and claiming requirements.

    • Clinical Policy Bulletin Notes and member plan provisions may include PA requirements not present in this excerpt.
    • Treating providers remain responsible for medical decisions and verifying benefit coverage.
    Step Therapy

    Conservative‑first implied — document trials of first‑line therapies before invasive/experimental options

    Conservative therapies (oral antivirals during acute HZ, tricyclic antidepressants, gabapentin, pregabalin, 5% lidocaine patch, opioids/tramadol) are identified as first‑line and are implied to be tried before higher‑risk or experimental interventions.

    • Document trials of guideline‑recommended systemic agents prior to escalation.
    • Intrathecal corticosteroids are noted as reserved for refractory cases and approached with caution.
    Step Therapy

    Preferred first‑ and second‑line pharmacologic therapies — document trials of guideline agents

    Preferred pharmacologic therapies endorsed in guideline summaries include tricyclic antidepressants, gabapentin, pregabalin, opioids, and lidocaine patch and should be used prior to considering less‑proven therapies.

    • Ensure documentation of trial and response to TCAs, gabapentin/pregabalin, or lidocaine patch when applicable.
    • Consider opioids only when guideline options are inadequate or contraindicated.
    Note

    No formal step‑therapy sequence specified in this excerpt

    No explicit step‑therapy sequencing or mandatory prior‑therapy durations are defined in this excerpt; the literature implies but does not mandate specific sequencing.

    • Policy excerpts do not establish a formal step‑therapy algorithm or fixed trial durations.
    • Providers should record reasonable trials of first‑line agents and clinical rationale for escalation.
    Step Therapy

    Conservative pharmacologic trial expected before invasive interventions

    Prior to invasive procedures such as DRG PRF or other nerve‑directed interventions, studies and the policy expect prior adequate trials of guideline‑recommended pharmacologic therapy (e.g., gabapentinoids) and documentation of inadequate response or intolerance.

    • Document prior gabapentin/pregabalin use, dosing, duration, and reason for discontinuation or inadequate response.
    • Record concomitant medications and any prior nerve block responses.
    Step Therapy

    Document conservative therapy attempts prior to interventional procedures

    Multiple interventional studies cited describe that patients had trials of conservative measures (anticonvulsants, antidepressants) before proceeding to interventional approaches; document these conservative therapy attempts when seeking authorization or billing.

    • Record medications tried, duration, and objective pain scores showing inadequate response.
    • Include rationale for escalation to interventional or topical high‑concentration therapies.
    Documentation Required

    Document intolerance or inadequate response to gabapentinoids when used as study inclusion rationale

    Some studies enrolled patients intolerant or insensitive to first‑line gabapentinoids before receiving CT‑guided ozone injections; when applicable, document intolerance or lack of efficacy to support use of less‑established interventions.

    • Document objective evidence of intolerance (adverse effects) or insufficient analgesia to gabapentin/pregabalin.
    • Include prior attempts at alternative first‑line agents if relevant.
    Note
    Billing Rule

    Coding and documentation linkage — bill listed codes only with required selection criteria

    Use the CPT/HCPCS/ICD-10 codes listed in the policy when submitting claims; covered codes require that the policy's selection criteria and clinical documentation be met to avoid denial.

    • Match the billed CPT/HCPCS codes to the procedures performed and provide supporting clinical documentation per the policy.
    • Covered CPT codes are only payable when selection criteria described in the policy are satisfied.
    Documentation Required

    Qutenza — required procedural documentation (anesthetic, patch count, 60‑minute application, ≥1‑hour monitoring)

    When performing Qutenza application, document topical anesthetic pretreatment, the number of patches applied (up to 4), 60‑minute application duration, and observe and record patient monitoring for at least 1 hour for blood pressure changes.

    • Record who applied the patch (trained health care professional), topical anesthetic used, and any additional analgesic measures.
    • Document monitoring data (BP) for at least 1 hour post‑application and any immediate adverse events.
    Note

    No additional universal provider documentation requirements specified in these excerpts

    This excerpt contains no general provider documentation mandates beyond procedure‑specific notes; follow plan benefit documentation requirements and Clinical Policy Bulletin Notes for any additional plan‑specific documentation.

    • No universal documentation checklist is specified in these chunks.
    • Providers retain responsibility for treatment decisions and should verify plan documentation expectations.
    Documentation Required

    Required clinical documentation for interventional procedures (baseline/follow‑up pain scores and prior therapy details)

    For interventional procedures document baseline pain scores (e.g., VAS/NRS), prior conservative treatments attempted, details of prior nerve blocks, and follow‑up pain assessments (1, 2, 4, 12 weeks) to support medical necessity and outcomes.

    • Include detailed procedural reports, imaging guidance used, and objective pain measures pre‑ and post‑procedure.
    • Record complications and subsequent medication changes during follow‑up visits.
    Documentation Required

    Required clinical documentation for capsaicin 8% patch (diagnosis, baseline pain, prior therapies, responses)

    Clinical documentation for capsaicin 8% patch use should include the diagnosis (PHN or peripheral neuropathic pain), baseline pain intensity (VAS/NRS), prior systemic and topical therapies tried, and responses to prior treatments.

    • Document prior medication trials and whether capsaicin is used as add‑on or first‑line in the treatment plan.
    • Record follow‑up pain scores and any adverse events such as high BP or local site reactions.
    Documentation Required

    For procedural reports, record demographics, VAS scores, and complications at 1, 6, 12 months

    Procedural reports in interventional studies commonly recorded demographics, VAS scores, and complications at 1, 6, and 12 months; include similar longitudinal data when claiming medical necessity for interventional approaches.

    • Include demographic and clinical baseline data, procedure details, and long‑term pain and complication monitoring.
    • Such documentation supports outcome assessment and potential continued authorization.
    Note
    Denial Risk

    Denial risk — do not bill listed not‑covered procedures/codes for PHN indications

    Claims for procedures or codes listed as not covered for indications in this policy (examples include pulsed radiofrequency of DRG, peripheral nerve stimulation, TENS devices/supplies, stellate ganglion block codes, neurostimulator implantation, extracorporeal shockwave code 0101T) may be denied when submitted for PHN.

    • Do not submit claims for listed not‑covered CPT/HCPCS codes for PHN indications unless plan guidance indicates otherwise.
    • Examples: PRF of DRG, TENS device/supplies (A4595, E0720, E0730), neurostimulator implantation (63650, 63655).
    Denial Risk

    Qutenza application and monitoring — trained applicator, anesthetic, 60‑minute application, ≥1‑hour BP monitoring

    Failure to have Qutenza applied by a trained health care professional, to follow application parameters (up to 4 patches, 60 minutes, repeat ≥3 months), or to monitor the patient for at least 1 hour for blood pressure rise after placement may conflict with product‑label procedures and the policy's application guidance.

    • Ensure documented application by a trained clinician, topical anesthetic pretreatment, and BP monitoring for ≥1 hour post‑application.
    • Repeat applications should not be performed more frequently than every 3 months per product labeling.
    Note

    No other explicit authorization or billing denial triggers specified in these excerpts

    No explicit provider authorization or billing denial triggers are stated in these excerpts beyond the not‑covered code lists; consult plan provisions for any additional denial risk factors.

    • The document excerpts do not define other explicit billing denial triggers.
    • Verify plan‑specific administrative rules for authorizations and denials.
    Denial Risk

    Predictive value of poor early response to TF ESI (<50% at 1 week) — may affect continued authorization

    A poor early response (<50% pain improvement) to an initial transforaminal epidural injection at 1 week predicted progression to PHN in a cited cohort and may influence decisions about continued interventions or authorization.

    • Document 1‑week post‑injection pain improvement; <50% improvement is a potential predictor of progression to PHN.
    • Use early response data to support clinical decisions about further interventions or authorization needs.
    Denial Risk

    Safety concern — trigeminal ganglion/ophthalmic‑division blocks can cause neurotrophic keratopathy/visual changes; document consent and monitoring

    Serious ocular adverse events (neurotrophic keratopathy, decreased visual acuity) have been reported after trigeminal (Gasserian) ganglion block; document informed consent, procedural details, and monitor for ocular complications when performing periorbital/ophthalmic‑division interventions.

    • Obtain and document informed consent discussing potential ocular risks.
    • Record imaging guidance used (fluoroscopy) and post‑procedure ocular assessments if applicable.
    Note

    Investigational therapies — document limited evidence and prior therapy failure; no automatic coverage in these excerpts

    Many interventional therapies described in these chunks are characterized as investigational or preliminary and no explicit authorization or coverage‑denial rules are provided here; larger well‑designed RCTs are needed before broader adoption.

    • When recommending investigational interventions, document rationale, prior conservative therapy failure, and discuss limited evidence with the patient.
    • Expect payers to require stronger evidence or case‑by‑case review for investigational procedures.
    Note

    CPB advisory — consult plan benefits; CPBs do not guarantee coverage

    Clinical Policy Bulletins assist in administering plan benefits but do not guarantee coverage; providers should verify member benefits and recognize they retain responsibility for medical decisions and treatment outcomes.

    • Consult member plan provisions and Clinical Policy Bulletin Notes for coverage and authorization specifics.
    • Providers are independent and responsible for clinical care; the CPB does not constitute a contract or coverage promise.

    Conservative Therapy Preconditions for Interventions

    Conservative therapies implied as first-line prior to experimental or higher-risk interventions; intrathecal corticosteroids reserved for refractory cases with caution

    Conservative therapies are expected before escalation to experimental or higher‑risk interventions; intrathecal corticosteroids are reserved for refractory cases with caution:

    Conservative‑first expectation: Standard conservative therapies (tricyclic antidepressants, gabapentin, pregabalin, topical 5% lidocaine patch, oral opioids/tramadol as appropriate, and oral antivirals during acute HZ) are identified as first‑line management and should be tried prior to consideration of experimental or higher‑risk interventional therapies for PHN.

    chunks 16,20

    Intrathecal corticosteroids reserved for refractory patients: There is evidence that intrathecal corticosteroids may be effective in patients refractory to conservative measures, but potential for neurological sequelae warrants caution and selective use.refractory to conservative measures

    chunk 16

    Qutenza procedural prerequisites: High‑concentration (8%) capsaicin patch (Qutenza) is a clinician‑applied procedure requiring topical anesthetic pretreatment, monitoring for at least 1 hour for blood‑pressure rise, and adherence to labeled application parameters (up to 4 patches applied for 60 minutes; repeat not more frequently than every 3 months); prior use of guideline‑recommended systemic therapies and documentation of refractory pain are commonly required by payers before approving procedure‑like application.repeat ≥3 months

    chunks 28,33 and authorization/prior‑auth notes (planner inv‑22, inv‑25)

    Conservative treatment expectations (no explicit top-level nodes in source)

    Clinical expectation regarding trials of conservative therapy before escalation:

    Preferred first‑line pharmacologic therapies: Guideline‑based preferred therapies include tricyclic antidepressants, gabapentin, pregabalin, topical 5% lidocaine patch, and when appropriate, opioids or tramadol; these agents should be used prior to considering less‑proven interventions.

    chunks 16,20

    Failure of conservative medical therapy prior to interventional treatment is implied in case reports

    Failure of adequate conservative medical therapy is implied before interventional treatment in the case reports and series cited:

    Case‑report/series implication: Reported trigeminal ganglion + retrobulbar block and transforaminal epidural steroid injection cases were undertaken after failure of conservative measures (anticonvulsants, antidepressants, topical therapies) and prior nerve blocks, indicating interventional treatment was applied for refractory PHN.failure of conservative measures documented

    chunks 46,62,72

    Prior adequate trial of guideline-recommended pharmacologic therapy before invasive interventions is implied by study designs

    Study designs and trial populations imply a prior adequate trial of guideline‑recommended pharmacologic therapy before invasive interventions:

    Prior trial of first‑line agents implied: Multiple interventional studies (e.g., PRF trials, IV zinc reports) enrolled patients who were receiving or had failed first‑line systemic neuropathic agents such as gabapentin or pregabalin, implying an expectation of prior adequate pharmacologic therapy before invasive procedures.trial of first‑line agents documented

    chunks 56–57

    Documented trial and inadequate response to first-line systemic neuropathic agents before invasive procedures is expected by the literature

    The literature generally expects documented trial and inadequate response to first‑line systemic neuropathic agents before invasive procedures are considered:

    Documented inadequate response expected: Case reports and review articles describe use of interventional trigeminal or peripheral nerve procedures after documented failure of anticonvulsants and antidepressants; clinical practice and study inclusion criteria commonly expect inadequate response to first‑line systemic neuropathic agents prior to invasive treatments.inadequate response to first‑line agents documented

    chunks 72,86

    Failure or intolerance of first-line gabapentinoids reported as inclusion for that study population

    Some interventional studies specifically enrolled patients intolerant of or refractory to gabapentinoids:

    Failure or intolerance of gabapentinoids as study inclusion: The CT‑guided intervertebral foramen ozone injection study enrolled patients intolerant of or insensitive to first‑line drugs such as gabapentin or pregabalin, reflecting that some investigational interventional studies select populations with prior gabapentinoid failure or intolerance.documented intolerance or insensitivity to gabapentinoids

    chunk 94

    Additional conservative-requirement related references and notes

    Additional conservative‑requirement references and operational notes drawn from the policy and cited studies:

    Operational expectation for prior therapies: When considering interventional or experimental procedures, clinical documentation should generally include baseline pain scores (e.g., VAS/NRS), list of prior conservative therapies tried (medication names, doses, durations), responses and intolerances, and prior procedural history (e.g., prior nerve blocks), consistent with the documentation described in the literature and policy notes.documentation of prior conservative therapies and baseline pain score

    chunks 16,62 and planner documentation notes

    Caveat on intrathecal corticosteroids: Although intrathecal corticosteroids have been reported effective in refractory patients, potential neurological risks require cautious consideration and selection of patients only after failure of standard therapies.refractory to multiple conservative therapies

    chunk 16

    Prior authorization / payer expectations:

    Application and Repeat Intervals

    Transforaminal epidural injections with imaging guidance (CPT 64479, 64483)
    CodesCPT 64479: transforaminal epidural injection, with imaging guidance (fluoroscopy or CT); cervical or thoracic, single level.
    Codes (additional)CPT 64483: transforaminal epidural injection, lumbar or sacral, single level (with imaging guidance specified).
    Imaging guidanceCode descriptions specify imaging guidance: fluoroscopy or CT required for 64479/64483 procedures.
    Qutenza (8% capsaicin patch) repeat application
    IntervalQutenza (8% capsaicin patch) repeat application: not more frequently than every 3 months (per product labeling).
    Application detailsApplied to most painful skin areas using up to 4 patches for 60 minutes by a health care professional; topical anesthetic and monitoring required.
    MonitoringPatient must be observed for at least 1 hour after placement because of risk of significant blood pressure rise.
    CT‑guided PRF targeting DRG
    Study parametersCT‑guided pulsed radiofrequency (PRF) targeting the thoracic dorsal root ganglion reported in a retrospective series (n=109) with PRF voltages of 45, 55, and 65 V and follow-up to 12 months.
    Frequency limitsNo policy frequency limits for CT‑guided DRG PRF are specified in the provided excerpt.
    Outcomes reportedVAS and SF-36 scores improved across groups; higher voltage (65 V) showed greater efficacy in that study.
    Transforaminal epidural steroid injection (TF ESI)
    Procedure exampleTransforaminal epidural steroid injection (TF ESI) described as a single-level thoracic TF ESI used for refractory PHN in case reports.
    Imaging guidanceTF ESI CPT codes (eg, 64479/64483) specify use of imaging guidance (fluoroscopy or CT) in code descriptions.
    Frequency/monitoringNo explicit standardized policy frequency limits for TF ESI are specified in the excerpt; documentation of prior conservative treatments and pain scores is described as important in study reports.
    Capsaicin 8% patch repeat applications
    Study observationsObservational series report mean of ~4.1 repeated high-concentration capsaicin (8%) patch applications in real-world cohorts (mean 4.1 applications reported).
    Product labelingProduct labeling states patches may be repeated every ≥3 months or as warranted by return of pain; no single standardized maximum frequency provided in excerpt.
    Safety findingsCommon local AEs include erythema, burning sensation, and transient pain; monitoring for blood pressure elevation reported in studies.
    Intervertebral foramen ozone injections
    Procedure descriptionIntervertebral foramen ozone injection (IVFO) is delivered under CT guidance into the intervertebral foramen for chronic thoracic/lumbar PHN.
    Repeat interventionsAuthors note repeated ozone interventions may be needed for some patients with a long disease course.
    Evidence levelStudy was non-randomized with small sample (n=56); authors call for larger RCTs to confirm safety and effectiveness.

    Imaging Guidance and Procedural Modality Notes

    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Interventions Considered Experimental / Not Medically Necessary

    The policy identifies numerous therapies and associated CPT/HCPCS codes that are considered not covered or experimental for PHN. Consolidated examples include: pulsed radiofrequency of the dorsal root ganglion (DRG PRF), peripheral nerve stimulation, transcutaneous electrical nerve stimulation (TENS) and related supplies, stellate ganglion block, sympathectomy, neurostimulator implantation and related surgical codes, extracorporeal shockwave therapy (0101T), and multiple HCPCS injectable codes listed as not covered for PHN indications.

    The policy's not‑covered lists are multi‑entry and include both CPT and HCPCS items; providers should reference the full code tables in the policy for the complete enumerated list when preparing claims or prior authorization requests.

    Duplicate or related not‑covered entries appear through the CPT listings (for example, codes related to neurolytic injections, neurostimulator implantation, destruction of somatic or sympathetic nerves, retrobulbar injections, and TMS). These duplicate listings reflect the policy's comprehensive enumeration of procedural codes that correspond to modalities judged experimental or not supported for PHN.

    Additional not‑covered or mixed‑status entries include TENS device and supply HCPCS codes (A4595; E0720, E0730, E0731), and multiple injectable agents and J‑codes that are either covered when selection criteria are met (various corticosteroid J‑codes) or listed among not‑covered items (e.g., J0133 acyclovir; J0585/J0587 botulinum toxins) depending on the indication.

    The HCPCS section mixes covered injectable corticosteroid codes (e.g., J1020, J1030, J1040, J2920, J2930) that may be allowable when policy selection criteria are satisfied with other HCPCS entries that are designated as not covered for PHN. Providers must consult the policy code tables and the corresponding coverage criteria when billing.

    The CPT lists include intercostal nerve block codes (64420‑64421), trigeminal nerve injection code (64400), stellate ganglion injection (64510), and retrobulbar injection codes (67500‑67505) among entries tied to procedures discussed in the policy. Some of these procedures are placed in the experimental/not covered grouping for PHN indications and are associated with the corresponding CPT entries listed here.

    Codes for implantation of peripheral or epidural neurostimulator systems and related surgical codes (e.g., 63650, 63655, 64555, 64575) are included in the policy's not‑covered procedural listings for PHN indications, reflecting the document's stance on neurostimulation procedures in this context.

    The policy enumerates CPT/HCPCS codes for device‑based therapies (e.g., 90867‑90869 for therapeutic rTMS, 95873‑95874 for electrical stimulation guidance) and procedure codes for destruction or neurolytic approaches (64600‑64640; 64680‑64681). Many of these are listed among codes related to modalities the policy considers experimental or not established for PHN.

    The HCPCS coding list includes injectable agents such as lidocaine injections (J2002, J2003), morphine and lorazepam injections (J2270, J2060), and other medications that are referenced in the clinical review; some injectable codes are shown as allowable when selection criteria are met while others are noted among not‑covered items for PHN indications.

    Phototherapy/photochemotherapy and iontophoresis have corresponding CPT codes listed (96910; 97033) and are mentioned among therapies with unproven or limited evidence for PHN in the policy code sections.

    Acupuncture CPT ranges (97810‑97814) and related alternative therapy entries are explicitly listed in the CPT/HCPCS sections; the policy lists acupuncture among modalities considered experimental or not proven for PHN indications in this CPB.

    The policy's background review characterizes evidence for systemic opioid formulations (including controlled‑release oxycodone and transdermal oxycodone patch) as very low quality with common adverse events. While these therapies are discussed in the evidence sections, the policy notes limited and low‑quality support rather than endorsing them as established therapies for PHN.

    The HCPCS lists include several medication J‑codes and supply codes that appear in mixed coverage status in the document; providers should reference the policy code tables and selection criteria to determine appropriate billing and coverage for specific injections and medications.

    Multiple entries in the CPT/HCPCS code lists reflect overlapping or related procedural items (e.g., neurolytic destruction codes, sympathetic procedures, neurostimulator implantation, nerve block and retrobulbar injection codes). These duplicate or related entries are preserved in the policy's comprehensive lists to map the range of procedural approaches discussed in the evidence review.

    Some HCPCS entries (for example, certain injectable agents and supplies) are explicitly called out as not covered in the context of PHN indications. The policy directs providers to the full code lists and the coverage rationale when submitting claims.

    Definitions and Key Term References

    Herpes zoster represents reactivation of varicella zoster virus in dorsal root ganglia producing a dermatomal rash and acute neuritic pain. Post‑herpetic neuralgia (PHN) is defined here as significant pain or dysaesthesia present 3 months or more after acute herpes zoster. Incidence of PHN increases with advanced age and immunocompromise and common pain types include continuous burning pain, paroxysms, and tactile allodynia.

    Post-herpetic neuralgia (PHN)
    DefinitionPost-herpetic neuralgia (PHN): significant pain or dysaesthesia present 3 months or more following acute herpes zoster.
    Epidemiology noteIncidence of HZ rises with age; more than 5% of the elderly have PHN at 1 year after acute HZ.
    DiagnosisPHN diagnosis is usually clinical based on typical unilateral dermatomal pain and history of HZ rash.
    Qutenza/NGX-4010
    ProductQutenza (NGX-4010): an 8% w/w topical capsaicin dermal patch applied by a health care professional for neuropathic pain associated with PHN.
    Application protocolApply up to 4 patches to the most painful skin areas for 60 minutes with topical anesthetic and additional pain control as needed; monitor patient for at least 1 hour post-application.
    Repeat dosingRepeat application per labeling not more frequently than every 3 months or as warranted by return of pain.
    Trigeminal (ophthalmic division) PHN interventional target
    TargetTrigeminal (ophthalmic division) PHN interventional target: first division of the trigeminal nerve (V1) and adjacent ocular neural structures.
    TechniquesInterventions described include trigeminal ganglion (Gasserian) block and retrobulbar nerve block using local anesthetic with steroid under fluoroscopic guidance.
    Evidence levelReported evidence is limited to case reports/series; findings require validation in larger studies and carry risk of ocular complications.
    Pulsed radiofrequency (PRF) of dorsal root ganglion (DRG)
    DefinitionPulsed radiofrequency (PRF) of the dorsal root ganglion (DRG): a neuromodulatory technique applying intermittent high-voltage pulses to DRG tissue intended to reduce pain signaling without producing a destructive thermal lesion.
    Evidence summarySystematic reviews and small RCTs/observational studies report preliminary positive findings but overall low-quality evidence; larger RCTs are needed.
    ApplicationsReported in studies as an adjunct to oral gabapentin or combined with transforaminal epidural steroid injections for PHN targeting thoracic/lumbar or cervical DRG.
    Repetitive transcranial magnetic stimulation (rTMS)
    DefinitionRepetitive transcranial magnetic stimulation (rTMS): noninvasive brain stimulation using repeated magnetic pulses (eg, 5‑Hz or 10‑Hz) applied to motor cortex to modulate pain networks.
    Protocol notesStudies used daily sessions (eg, 1,500 pulses/session) over 10 days with stimulation intensity ~80% RMT; parameters and optimal protocol vary across trials.
    EvidenceSmall RCTs and a meta-analysis (5 RCTs, 257 patients) suggest rTMS reduces VAS and may improve patient-reported outcomes versus sham, but heterogeneity and small sample sizes limit certainty.
    Trigeminal ganglion (Gasserian) block
    DefinitionTrigeminal ganglion (Gasserian) block: an interventional procedure targeting the trigeminal (Gasserian) ganglion using local anesthetic and/or steroid under fluoroscopic guidance for refractory ophthalmic-division PHN.
    TechniqueMay be combined with retrobulbar block to address residual oculodynia; performed under image guidance due to proximity to ocular structures.
    Safety noteCase reports indicate potential ocular complications (eg, neurotrophic keratopathy) and limited evidence base—requires careful consideration and further study.
    Capsaicin 8% patch (Qutenza)
    Product identityCapsaicin 8% patch (Qutenza): a high-concentration topical capsaicin formulation indicated for PHN and diabetic peripheral neuropathy and applied by a health care professional.
    Indications and useApproved for neuropathic pain associated with PHN; applied for 60 minutes, up to 4 patches, requires topical anesthetic and monitoring for blood pressure changes.
    Safety/AE profileLocal site reactions (erythema, burning, pain) are common; transient blood pressure increases and site pain reported in trials and observational studies.
    miR-34c-5p
    BiomarkermiR-34c-5p: a serum microRNA measured by RT-qPCR reported elevated in PHN patients and proposed as a potential diagnostic biomarker correlated with pain and rehabilitation outcomes.
    Diagnostic performanceReported sensitivity 79.2% and specificity 84.3% to distinguish PHN patients from healthy controls in the cited study (n=154 PHN vs 108 controls).
    Research statusFindings are preliminary and require further validation before routine clinical use.
    IVFO (intervertebral foramen ozone injection)
    ProcedureIVFO (intervertebral foramen ozone injection): CT-guided injection of medical ozone into the intervertebral foramen for chronic thoracic and lumbar PHN.
    Patient selectionStudy enrolled patients intolerant or insensitive to first-line drugs (gabapentin/pregabalin); reported significant VAS improvements up to 1 year.
    Repeat treatmentsAuthors noted repeated ozone interventions may be required for some patients with long disease course; larger RCTs are needed.
    PRF + TFAESI
    DefinitionPRF + TFAESI: combined pulsed radiofrequency applied to the dorsal root ganglion and transforaminal anterior epidural steroid injection used to treat HZ-related pain/PHN.
    EvidenceRetrospective series (n=93) and small randomized trials report reduced VAS scores at 1, 6, and 12 months post-procedure; evidence remains preliminary.
    Procedural notesProcedures reported were performed at multiple spinal levels under CT or fluoroscopic guidance per study descriptions.
    Definitions (policy reference)
    Definitions sectionThe policy references a Definitions section via link but no additional definitions are contained in the cited document chunks.
    NavigationSee the policy 'Definitions' link for expanded terminology used elsewhere in the Clinical Policy Bulletin.
    Scope noteThis CPB's Definitions link is provided for reference; specific terms within these excerpted chunks are defined individually where cited.

    Policy Dates and Revision Notes

    2006-06-20policy_effective

    Policy effective date recorded as 06/20/2006.

    2009-11-17regulatory_event

    FDA approval/news for NGX-4010 (high-concentration capsaicin patch) documented by FDA on 2009-11-17.

    2025-10-20policy_reviewLatest

    Most recent policy review completed on 2025-10-20.

    Policy administrative dates
    Effective dateEffective: 06/20/2006
    Last reviewLast review: 10/20/2025
    Next scheduled reviewNext review: 08/13/2026
    For procedure‑like interventions (e.g., Qutenza application) or interventional injections, payer prior authorization (where required) may request documentation of prior conservative therapy failure and adherence to procedure‑specific requirements (e.g., Qutenza application parameters and monitoring), as reflected in the policy and authorization notes.
    prior conservative therapy documented; adherence to procedural parameters

    chunks 33,28, planner prior_auth items